| Literature DB >> 25032194 |
Chi-Feng Hung1, Cheng-Kuang Yang2, Yen-Chuan Ou2.
Abstract
PURPOSE: The aim of this study was to assess surgical, oncologic and functional results after robotic-assisted laparoscopic radical prostatectomy (RALP) with and without previous transurethral resection of the prostate (TURP).Entities:
Keywords: Prostatectomy; Prostatic neoplasm; Robotics; Transurethral resection of prostate
Year: 2014 PMID: 25032194 PMCID: PMC4099399 DOI: 10.12954/PI.14046
Source DB: PubMed Journal: Prostate Int ISSN: 2287-8882
Preoperative characteristics, preoperative variables during robotic-assisted laparoscopic prostatectomy in the two groups
| Variable | TURP | ||
|---|---|---|---|
|
| |||
| Group 1 (Yes, n=16) | Group 2 (No, n=184) | ||
| Age (yr) | 67.5±7.4 | 64.8±6.9 | 0.134 |
| Body mass index (kg/m2) | 25.2±3.5 | 24.5±2.8 | 0.400 |
| ASA physical status classification system | 0.112 | ||
| 1 | 0 (0) | 40 (21.7) | |
| 2 | 14 (87.5) | 128 (69.6) | |
| 3 | 2 (12.5) | 16 (8.7) | |
| PSA (ng/mL) | 26.44±29.59 | 17.85±20.27 | 0.271 |
| Free PSA (ng/mL) | 3.51±4.71 | 2.02±2.20 | 0.080 |
| PSA density | 0.67±0.54 | 0.52±0.57 | 0.333 |
| Biopsy percentage | 33.4±26.0 | 21.6±20.5 | 0.032 |
| Gleason score | 6.63±1.02 | 6.59±1.08 | 0.892 |
| Clinical stage | 0.451 | ||
| T1 | 8 (50.0) | 71 (38.6) | |
| T2 | 8 (50.0) | 101 (54.9) | |
| T3 | 0 (0) | 12 (6.5) | |
Values are presented as mean±standard deviation or number (%).
TURP, trans-urethral resection of prostate; PSA, prostate-specific antigen.
Patient perioperative data and complications using the Clavien classification system
| Variable | TURP | ||
|---|---|---|---|
|
| |||
| Group 1 (Yes, n=16) | Group 2 (No, n=184) | ||
| Vesicourethral anastomosis (min) | 32.6±19.9 | 30.3±10.2 | 0.432 |
| Need for reconstruction of bladder neck | 15 (93.75) | 28 (15.21) | <0.001 |
| Console time (hr) | 3.16±1.74 | 2.95±0.78 | 0.367 |
| Blood loss (mL) | 145.0±161.4 | 183.2±18.06 | 0.416 |
| Transfusion | 0 (0) | 7 (3.8) | 1.000 |
| BPLND | 14 (87.5) | 153 (83.2) | 1.000 |
| Complications | 4 (25.0) | 20 (10.9) | 0.108 |
| Clavien grade I | 1 (25.0) | 5 (25.0) | 0.004 |
| Clavien grade II | 0 (0) | 13 (65.0) | |
| Clavien grade III | 1 (25.0) | 2 (10.0) | |
| Clavien grade IV | 2 (50.0) | 0 (0) | |
| Minor (Clavien grade I–II) | 1 (6.3) | 18 (9.8) | <0.001 |
| Minor (Clavien grade III–V) | 3 (18.8) | 2 (1.1) | |
| No complication | 12 (75.0) | 164 (89.1) | |
| Rectal injury | 3 (18.75) | 0 (0) | <0.001 |
| Anastomosis stricture | 0 (0) | 2 (1.08) | 1.000 |
Values are presented as mean±standard deviation or number (%).
TURP, trans-urethral resection of prostate; BPLND, bilateral pelvic lymph node dissection.
Clavien system: grade I, deviate from the normal postoperative course without treatment; grade II, drug or bedside treatment; grade III, endoscopic (IIIa) or surgical intervention (IIIb); grade IV, life-threatening problem, single organ (IVa) or multiorgan (IVb); grade V, death; minor, I–II; major, III–V.
Patient postoperative and oncologic results
| Variable | TURP | ||
|---|---|---|---|
|
| |||
| Group 1 (Yes, n=16) | Group 2 (No, n=184) | ||
| Foley catheter (day) | 9.31±2.82 | 9.00±2.57 | 0.644 |
| Postoperative stay (day) | 4.19±2.01 | 3.77±2.26 | 0.477 |
| Pathology stage | |||
| pT2 | 4 (25.0) | 74 (40.2) | 0.128 |
| pT3 | 10 (62.5) | 104 (56.5) | |
| pT4 | 2 (12.5) | 6 (3.3) | |
| Surgical margin positive | 7 (43.8) | 74 (40.2) | 0.992 |
| pT2 | 1 (25.0) | 4 (5.4) | 0.610 |
| pT3 | 4 (40.0) | 64 (61.5) | 0.199 |
| pT4 | 2 (100) | 6 (100) | |
| Specimen volume (mL) | 31.63±8.82 | 45.49±20.99 | <0.001 |
| Tumor volume | 7.43±6.88 | 11.05±11.73 | 0.226 |
| Tumor percentage | 22.81±21.21 | 25.86±24.47 | 0.631 |
| Pathology Gleason score | |||
| 2–4 | 0 (0) | 2 (1.1) | 0.179 |
| 5–7 | 16 (100) | 151 (82.1) | |
| 8–10 | 0 (0) | 31 (16.8) | |
| Node positive | 1 (6.3) | 12 (6.52) | 1.000 |
| PSA failure | 3 (18.8) | 21 (11.4) | 0.416 |
Values are presented as mean±standard deviation or number (%).
TURP, trans-urethral resection of prostate; ASA, American Society of Anesthesiologists; PSA, prostate-specific antigen.
Functional results after RALP and neurovascular bundle preservation
| Variable | TURP | ||
|---|---|---|---|
|
| |||
| Group 1 (Yes, n=16) | Group 2 (No, n=184) | ||
| Continence within | |||
| 1 Week | 4 (25.0) | 72 (39.1) | 0.396 |
| 1 Months | 9 (56.3) | 114 (62.0) | 0.855 |
| 3 Months | 14 (87.5) | 172 (93.5) | 0.310 |
| 6 Months | 15 (93.8) | 179 (97.3) | 0.398 |
| 12 Months | 15 (93.8) | 180 (97.8) | 0.344 |
| Attempt to NVB preservation | 6 (37.5) | 88 (47.8) | 0.594 |
| Successful NVB preservation | 2 (33.3) | 81 (92.0) | 0.001 |
| Incidence NVB preservation | 2 (12.5) | 81 (44.0) | 0.029 |
| Potency at 12 months | 2 (100) | 65 (80.3) | 1.000 |
| Bilateral NVB | 2 (100) | 48 (73.8) | 1.000 |
| Unilateral NVB | 0 (0) | 17 (26.2) | |
Values are presented as number (%).
RALP, robotic-assisted radical prostatectomy; TURP, transurethral resection of prostate; NVB, neurovascular bundle.
Surgical, oncologic and functional results after open radical retropubic prostatectomy (RRP), laparoscopic radical prostatectomy (LRP), extraperitoneal laparoscopic radical prostatectomy (ELRP) and robotic-assisted radical prostatectomy (RALP) with and without previous transurethral resection of the prostate (TURP) in the literature
| Investigator | Technique | Perioperative outcome & complication rate | Oncological outcome | Functional outcome |
|---|---|---|---|---|
| Palisaar et al. [ | RRP | No higher complication rate | Insignificantly higher PSM rate and PSA failure rate | Similar complete urinary control rate |
| Colombo et al. [ | RRP | Longer operative time | Insignificantly higher PSM rate and PSA failure rate | Less satisfactory functional results |
| Do et al. [ | ELRP | Comparable perioperative outcome | Comparable oncological outcome | Similar continence rate |
| Teber et al. [ | LRP | Longer operative time | Comparable oncological outcome | Delayed continence time |
| Menard et al. [ | LRP | Worse perioperative outcome | Comparable oncological outcome | Similar continence rate |
| Jaffe et al. [ | LRP | Longer operative time, length of stay | Higher PSM rate | NR |
| Eden et al. [ | LRP | Longer catheterization time | Similar PSM rate | Delayed continence time |
| Martin et al. [ | RALP | Longer catheterization time | Similar PSM rate | NR |
| Gupta et al. [ | RALP | Greater blood loss and a need for bladder neck reconstruction | Higher PSM rate | Higher incontinence rate |
| Zugor et al. [ | RALP | More need for bladder neck reconstruction | Comparable PSM rate | Delayed continence and potency time |
| Present study | RALP | More need for bladder neck reconstruction | Comparable PSM rate and PSA recurrence rate | Similar continence rate |
PSM, positive surgical margin; PSA, prostate-specific antigen; NR, not recorded; NVB, neurovascular bundle.